Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis

计划入组 20 人 · 首次发布于 2024 年 10 月 31 日

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

计划入组 454 人 · 首次发布于 2024 年 7 月 19 日

A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.

计划入组 25 人 · 首次发布于 2024 年 4 月 30 日

Nadofaragene firadenovec-vncg(Adstiladrin)

Sitimagene ceradenovec

Golnerminogene pradenovec

Ferring Advances Nadofaragene Firadenovec Clinical Program in Urothelial Cancers

Ferring Expands Adstiladrin Production Capacity with New Facility in Finland

FDA Approves Ferring Pharmaceuticals' New Manufacturing Facility for Bladder Cancer Gene Therapy ADSTILADRIN